Navigation Links
DRAXIS Share Buyback Approved by TSX
Date:1/16/2008

MONTREAL, Jan. 16 /PRNewswire-FirstCall/ - DRAXIS Health Inc, (TSX: DAX) (NASDAQ: DRAX) has received approval from the Toronto Stock Exchange (TSX) for its previously announced Normal Course Issuer Bid (NCIB) to purchase up to 4,072,054 common shares, which represent approximately 10% of the 40,720,539 common shares in the public float as at January 14, 2008. As at January 14, 2008, 42,062,538 common shares of DRAXIS were issued and outstanding.

Purchases may begin on January 21, 2008 and the bid will end no later than January 20, 2009 or earlier if the Company purchases the maximum allowable number of shares. All shares will be purchased through the facilities of the TSX and will be cancelled. During the previous twelve months, DRAXIS purchased 130,100 of its common shares at an average price of CDN$5.21 under a previous NCIB.

The Board of Directors of DRAXIS believes that the underlying value of DRAXIS is not reflected in the current market price of its common shares, and may not be so reflected at certain times during the course of the NCIB, and has thus concluded that the repurchase of common shares pursuant to the proposed NCIB presently constitutes an appropriate use of financial resources and would be in the best interest of shareholders.

Any purchases made pursuant to the NCIB will be made in accordance with the rules of the TSX and will be made at the market price of the common shares at the time of the acquisition. DRAXIS will make no purchases of common shares other than open market purchases which may be made during the period that the NCIB is outstanding. Subject to any block purchases made in accordance with the rules of the TSX, DRAXIS will be subject to a daily repurchase restriction of 23,084 common shares, which represent 25% of the average daily trading volume of DRAXIS' common shares on the TSX for the 6 months ended December 31, 2007.

About DRAXIS Health Inc.

DRAXIS Health, through its wholly owned operating subsidiary, DRAXIS Specialty Pharmaceuticals Inc., provides products in three categories: sterile products, non-sterile products and radiopharmaceuticals. Sterile products include liquid and freeze-dried (lyophilized) injectables plus sterile ointments and creams. Non-sterile products are produced as solid oral and semi-solid dosage forms. Radiopharmaceuticals are used for both therapeutic and diagnostic molecular imaging applications. Pharmaceutical contract manufacturing services are provided through the DRAXIS Pharma division and radiopharmaceuticals are developed, produced, and sold through the DRAXIMAGE division. DRAXIS employs approximately 500 staff in its Montreal facility.
For additional information please visit http://www.draxis.com

Caution Concerning Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and as contemplated under other applicable securities legislation. These statements can be identified by the use of forward-looking terminology such as "may," "will," "expect," "anticipate," "estimate," "continue," "plan," "intend," "believe" or other similar words. These statements discuss future expectations concerning results of operations or financial condition or provide other forward-looking information. Our actual results, performance or achievements could be significantly different from the results expressed in, or implied by, those forward-looking statements. You should not place undue reliance on any forward-looking statement, which speaks only as of the date made.

These statements are not guarantees of future performance. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks, uncertainties and other factors that may cause the actual results or performance of the Company to be materially different from such statements or from any future results or performance implied thereby. Factors that could cause the Company's results or performance to differ materially from a conclusion, forecast or projection in the forward-looking statements include, but are not limited to:

- the achievement of desired clinical trial results related to the

Company's pipeline products;

- timely regulatory approval of the Company's products;

- the ability to comply with regulatory requirements applicable to the

manufacture and marketing of the Company's products;

- the Company's ability to obtain and enforce effective patents;

- the non-infringement of third party patents or proprietary rights by

the Company and its products;

- factors beyond our control that could cause interruptions in our

operations in our single manufacturing facility (including, without

limitation, material equipment breakdowns);

- reimbursement policies related to health care;

- the establishment and maintenance of strategic collaborative and

commercial relationships;

- the Company's dependence on a small number of key customers;

- the disclosure of confidential information by our collaborators,

employees or consultants;

- the preservation of healthy working relationships with the Company's

union and employees;

- the Company's ability to grow the business;

- the fluctuation of our financial results and exchange and interest

rate fluctuations;

- the adaptation to changing technologies;

- the loss of key personnel;

- the avoidance of product liability claims;

- the loss incurred if current lawsuits against us succeed;

- the volatility of the price of our common shares;

- market acceptance of the Company's products;

- factors described under "Outlook" in the Company's MD&A for the most

recent quarter; and

- the risks described in "Item 3. Key Information - Risk Factors" in the

Annual Report Form 20-F filed by the Company with the United States

Securities and Exchange Commission and which is also filed as the

Company's Annual Information Form with Canadian securities regulators.

For additional information with respect to certain of these and other factors, and relating to the Company generally, reference is made to the Company's most recent filings with the United States Securities and Exchange Commission (available on EDGAR at http://www.sec.gov) and the filings made by the Company with Canadian securities regulators (available on SEDAR at http://www.sedar.com). The forward-looking statements contained in this document represent the Company's expectations as at January 15, 2008. Unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE DRAXIS Health Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. DRAXIS Announces Application for Normal Course Issuer Bid
2. DRAXIS Names GE Healthcare as Exclusive Distributor of DRAXIMAGE(R) Sestamibi in USA
3. DRAXIS Health Inc. Announces Retirement of Dr. Martin Barkin as President and Chief Executive Officer
4. DRAXIS to Present at the 2007 UBS Global Life Sciences Conference
5. Draxis Health selected by Johnson and Johnson Consumer Companies, Inc. for major contract manufacturing relationship
6. Regence Enables Members to Share Feedback With Each Other When Researching Health Care Provider Options
7. AlphaRx CEO Accumulates More Company Shares
8. Private Equitys Top Execs to Share Advice, Candid Predictions at 2008 Outlook Conference
9. HearAtLast Holdings, Inc. Provides Shareholder Update
10. QED International Associates Announces Changes to the HealthShares(TM) Emerging Cancer Index
11. Body Abnormalities, Childhood Cancer May Share Genes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2017)... ... 2017 , ... PIXACORE , an independent full-service agency with a decade ... of the year by MM&M. , This is the first time PIXACORE has made ... the agency. PIXACORE’s newfound recognition reflects its steady trajectory of growth and recent ...
(Date:8/21/2017)... , ... August 21, 2017 , ... San Diego physician ... health care reform plan, has announced his candidacy for the 52nd Congressional District currently ... shared in America’s Promise. Coming to this country at age eleven after suffering homelessness ...
(Date:8/21/2017)... Atlanta, GA (PRWEB) , ... August 21, 2017 , ... ... International Design Excellence Awards (IDSA IDEA®) 2017 Ceremony and Gala on Aug. 19, ... Silver in one of the world’s most prestigious and rigorous design competitions. See all ...
(Date:8/20/2017)... Land Texas (PRWEB) , ... August 20, 2017 ... ... announce that the HIPAA ComplyPAK™ Compliance Management System has assisted multiple ... Institute of Certified Public Accountants, Service Organization Control Level 2 (AICPA SOC Level ...
(Date:8/20/2017)... ... August 20, 2017 , ... Are you an adult with gluten ... so, you may be interested in participating in a research study that focuses on ... to understand more about the relational aspects of adults who have gluten sensitivities who ...
Breaking Medicine News(10 mins):
(Date:8/4/2017)... 2017 The search for test results that ... consult has long been the goal of healthcare providers ... of the largest meeting of lab professionals and IVD ... research firm Kalorama Information.  The firm said scores of ... related supplies and software were at the American Association ...
(Date:8/2/2017)... Aug. 2, 2017 Fenita J. ... as a Pinnacle Lifetime Professional in the Field ... Manager at Turing Pharmaceuticals, AG. Her skills and ... relationship building.                ... 25 years of experience as a highly successful ...
(Date:8/2/2017)... , Aug. 2, 2017 CaryRx, a next-generation full-service ... delivery service for patients in the Washington D.C. ... retail pharmacy by providing delivery of medications through the convenience ... future delivery or delivered within one hour to any location ... excited to bring this invaluable service to Washington ...
Breaking Medicine Technology: